RIGL

Over the past six months, Rigel Pharmaceuticals' stock has declined by 25.36%, and year-to-date, it is down 38.40%, but it rose by 38.73% over the last 12 months. Key events include Q1 2026 financial results with net product sales of just under $55 million, a 26% increase compared to the first quarter of 2025, Q4 and full year 2025 financial results with preliminary total revenue for Q4 2025 was approximately $69.8 million, with net product sales of $65.4 million, publication of GAVRETO clinical data in the Journal of Clinical Oncology, inducement grants to non-executive employees, a stock price increase in November 2025 benefiting institutional investors, and a capital raise in late 2024 to finance the expansion of the IRAK1/4 program.